Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

Pfizer agrees to $5.4B deal for Global Blood Therapeutics

Pfizer agrees to $5.4B deal for Global Blood Therapeutics

Pfizer Inc. has agreed to buy Global Blood Therapeutics Inc. for $5.4 billion, in a deal that would give the big drugmaker a foothold in the treatment of sickle-cell disease.

Pfizer said Monday it would pay $68.50 a share in cash for Global Blood Therapeutics, which has one of the few approved treatments for sickle-cell disease. The Wall Street Journal reported Friday that the companies were in advanced talks.

The acquisition continues a string of deals for Pfizer, which is flush with cash from sales of its Covid-19 vaccine and drug. It has said it wants to add $25 billion in revenue from business-development moves like mergers and acquisitions by 2030.

Adding Global Blood Therapeutics would bolster Pfizer's rare-diseases business and help it realize a longtime goal of selling drugs to treat sickle cell, an inherited blood disorder that affects about 100,000 people in the U.S. and 20 million worldwide, including many who are Black.


In patients with the disease, red blood cells look like crescents or sickles, rather than a normal disc shape. Due to their shape, the cells don't move easily and can block blood flow, damage organs and lead to strokes.

Researchers have been trying to develop effective treatments, including gene therapies, but the disease has proven hard to treat. A handful of drugs are approved, but most target the complications of sickle-cell disease, rather than its underlying cause. A bone-marrow transplant is the only cure.

New York-based Pfizer had tried to develop its own sickle-cell drug, but it failed.

In 2019, Global Blood Therapeutics won approval in the U.S. for a sickle-cell drug named Oxbryta. It has two other sickle-cell drugs in development.

"The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle-cell disease community and bring these treatments to patients as quickly as possible," Pfizer Chief Executive Albert Bourla said.

Oxbryta produced $195 million in net sales last year for Global Blood Therapeutics, which is based in South San Francisco, Calif.

If each of the three Global Blood Therapeutics drugs is approved, the franchise has multibillion-dollar sales potential, especially if Pfizer can fold them into its global commercial network and market them worldwide, according to analysts.

"Pfizer will broaden and amplify our impact for patients and further propel much needed innovation," Global Blood Therapeutics Chief Executive Ted Love said.

The drugs could eventually face competition from gene therapies, however. Swiss drugmaker Novartis AG sells Adakveo, a treatment for pain crises in sickle-cell patients 16 years of age and older.

Pfizer's purchase, together with a recent agreement by Amgen Inc. to buy ChemoCentryx Inc., could help turn Wall Street sentiment on biotech shares. The former highfliers have slumped in recent months due to market turmoil, scientific setbacks and fear of antitrust scrutiny of combinations.

Newsletter

Related Articles

0:00
0:00
Close
Italian Activist Ilaria Salis Returns Home After Election to European Parliament
England Faces Serbia in Euro Opener with Defensive Concerns
Dermatologist Warns Against Sunbed Usage
UK Man Jailed for Non-Consensual Condom Removal
US, Britain, Canada Accuse Russia of Interference in Moldova’s Election
EU Urged to Welcome Skilled Russians to Weaken Putin
EU Elections Overview: Far-Right Gains and Major Political Shifts
Israel Rescues Four Hostages from Gaza
Emmanuel Macron Calls for Snap Election
Jordan Bardella: Young Far-Right Leader Poised for Future Political Influence in France
Dutch Military Intel Uncovers Extensive Chinese Cyber Espionage
Turkish Student Arrested for Using AI to Cheat in University Exam
Rise in Dengue and Other Mosquito-Borne Diseases in Europe Due to Climate Change
Far-Right National Rally Dominates France's EU Vote
Macron Calls Snap Legislative Elections After Far-Right Victory
Far-Right Gains Significantly in EU Election
Orban’s Fidesz Party Wins Majority in Hungary’s EU Elections as New Challenger Emerges
Meloni's Far-Right Party Wins European Elections in Italy
Key Insights from the European Union Elections
European Union Elections and Rise of Far-Right Parties
Macron Dissolves Parliament and Calls Snap Elections
Russia Adds Yulia Tymoshenko to Wanted List
Danish Prime Minister Mette Frederiksen Assaulted in Central Copenhagen
Germany and France Oppose EU Luxury Car Restrictions to Russia
French Citizen Arrested in Russia for Alleged Military Intelligence Gathering
Germany's Defense Minister Calls for War Preparedness by 2029
Deutsche Bank Revises Eurozone GDP Outlook for 2023
Widening Wealth Gap in Europe
FTI Group Files for Insolvency, Affecting Thousands of Travelers
Germany Announces €23 Billion Tax Cuts to Support Inflation-Hit Households
West Nears Plan to Tap $300bn in Frozen Russian Assets
The European Central Bank (ECB) has cut interest rates for the first time in nearly five years
Putin Warns Against Western Arms Deliveries to Ukraine
Slovak PM Blames Opposition for Assassination Attempt
Study Finds Covid Vaccines May Have Contributed to Excess Deaths
EU Commission Considers Broader Digital Surveillance Measures
Macron to Host Zelensky in Paris for Crucial Talks
Italy's Prime Minister Meloni to Visit Migrant Centers in Albania
Conservatives Plan to Define Sex as Biological in Equality Act
China Accuses MI6 of Recruiting Chinese Government Staff as Spies
Nigel Farage Makes Eighth Attempt to Become UK MP
UK Poll Predicts Historic Victory for Labour Party
Orban Amplifies Anti-NATO Rhetoric Ahead of Elections
Meloni Urges EU Parliament to Adopt Right-Wing Coalition Model
Venice Implements New Tourist Restrictions
Chinese Vice Foreign Minister Urges US to Stop 'Smearing' China
Hungary Commits to Enhancing Investment and Trade with Cambodia
The Reality of Social Europe: Homes, Training, and Jobs
China Warns EU Against Tariffs on Electric Vehicles
Chinese EV Makers Target European Market with Competitive Prices
×